Trial
NCT05265728
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Biogen
Collaborators
—
Condition
Multiple Sclerosis, Relapsing-Remitting
Intervention
Natalizumab
Why stopped
Due to sponsor decision, not for efficacy or safety reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-25